Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.
Apyx Medical Corporation (NASDAQ: APYX) is a surgical aesthetics and advanced energy technology company whose news flow centers on its Helium Plasma Platform Technology products, including Renuvion, the AYON Body Contouring System, and J-Plasma. Company press releases focus on developments in the cosmetic surgery market, the hospital surgical market, and OEM relationships with other medical device manufacturers.
Investors and observers following APYX news will see regular updates on financial performance, such as quarterly and annual revenue results, preliminary unaudited revenue ranges, and segment-level trends in Surgical Aesthetics and OEM revenue. The company also issues guidance updates and discusses factors influencing its revenue mix, including the commercial rollout of AYON and demand for single-use handpieces and generators.
Another key category of Apyx Medical news involves product and regulatory milestones. Recent announcements describe FDA 510(k) clearances and submissions related to the AYON Body Contouring System, as well as international regulatory approvals like the Ministry of Food and Drug Safety clearance in South Korea for the Apyx One console and single-use handpieces. These items highlight how the company is expanding the indications and geographic reach of its platforms.
APYX news also covers capital markets and corporate actions, including proposed and completed public offerings of common stock under an effective Form S-3 shelf registration statement, as reported in 8-K filings and related press releases. Additional items include notices of investor conference participation, inducement equity awards under Nasdaq Listing Rule 5635(c)(4), and information about annual stockholder meetings and governance matters.
This news page aggregates these disclosures so readers can review Apyx Medical’s earnings releases, product launch updates, regulatory submissions, financing transactions, and investor events in one place.
Apyx Medical (NASDAQ: APYX) announced that Renuvion won the 2026 NewBeauty Award for Best Minimally Invasive Skin Tightener, marking a consecutive win and third-party recognition of its clinical impact and market position.
According to the company, Renuvion is FDA-cleared for use following liposuction and pairs with the AYON platform to broaden physician workflow and procedural options.
Apyx Medical (NASDAQ:APYX) reported Q4 2025 total revenue of $19.2M and full-year 2025 revenue of $52.8M, driven by a commercial launch of the AYON Body Contouring System in September 2025. Surgical Aesthetics revenue rose 38.1% in Q4 and 17.4% for FY2025. Q4 adjusted EBITDA was positive at $0.7M; FY2025 adjusted EBITDA loss narrowed to $3.8M. The company ended 2025 with $31.7M cash and expects FY2026 revenue of $57.5M–$58.5M and operating expenses under $45.0M. A 510(k) submission for AYON power liposuction is anticipated to be cleared mid-2026.
Apyx Medical (NASDAQ:APYX) will release fourth-quarter fiscal 2025 financial results before markets open on March 10, 2026. Management will host a conference call and webcast at 8:00 a.m. ET the same day to discuss results and take questions.
Phone dial‑in access, an international number, and an archived webcast will be available via the company’s investor relations site.
Apyx Medical (NASDAQ:APYX) said management will participate in The Citizens Life Sciences Conference on Wednesday, March 11, 2026, in Miami, FL. CEO Charlie Goodwin and CFO Matt Hill will take part in a fireside chat at 8:25am ET and hold investor meetings throughout the day.
The fireside chat will be available via live webcast, with a replay posted in the Events section of Apyx Medical’s Investor Relations website.
Apyx Medical (NASDAQ:APYX) said management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 10, 2026 in Snowbird, Utah.
Investors seeking meetings should contact their BTIG representatives. The company highlighted its Renuvion, J-Plasma, and FDA-cleared AYON Body Contouring System and noted more than 90 supporting clinical documents.
Apyx Medical (Nasdaq: APYX) reported preliminary, unaudited revenue for Q4 and full year 2025. Q4 2025 total revenue is expected to be approximately $19.0–$19.2M (+~34% YoY), driven by Surgical Aesthetics of $16.6–$16.8M (+~38% YoY) and OEM revenue of ~$2.4M (+~13% YoY). Apyx cited a U.S. Surgical Aesthetics increase of ~51% following the AYON commercial launch. For full year 2025, total revenue is expected at $52.7–$52.9M (+~10% YoY), Surgical Aesthetics $45.2–$45.4M (+~17% YoY), and OEM ~$7.5M (−21% YoY). The company will release audited results in March 2026; figures are preliminary and subject to closing and audit procedures.
Apyx Medical (Nasdaq: APYX) announced MFDS approval and the commercial launch of the Apyx One console and single-use handpieces for cosmetic surgical procedures in South Korea.
The company plans to begin shipping to fill initial orders starting in Q4 2025. Apyx One combines Renuvion technology with monopolar and bipolar energy and features adaptive touch screens, procedural presets, energy quantification, and an advanced gas-monitoring system.
Management cited South Korea’s cosmetic surgery market estimate of $1.7 billion in 2024 and a projected increase to $3.9 billion by 2033, and noted increased demand tied to GLP-1 weight-loss drug use and subsequent body-contouring needs.
Apyx Medical (Nasdaq: APYX) priced an underwritten public offering of 2,762,431 shares of common stock at $3.62 per share, representing gross proceeds of approximately $10.0 million. The company granted the underwriter a 45-day option to purchase up to an additional 414,365 shares at the public offering price less underwriting discounts.
The offering is expected to close on or about November 19, 2025, subject to customary closing conditions. Net proceeds are intended for working capital and general corporate purposes. Lucid Capital Markets is sole book-runner. The offering is made under a shelf registration statement declared effective December 2, 2022.
Apyx Medical (Nasdaq: APYX) announced on November 17, 2025 that it has commenced a proposed underwritten public offering of common stock or common stock equivalents, subject to market conditions.
Lucid Capital Markets is sole book-running manager. The offering will be made from a shelf registration on Form S-3 (File No. 333-268532) declared effective December 2, 2022; a preliminary prospectus supplement and prospectus will be filed with the SEC and posted at www.sec.gov when available. The company cautioned there is no assurance the offering will be completed on the anticipated terms.
Company products include Renuvion, AYON Body Contouring System (FDA-cleared), and J-Plasma, supported by more than 90 clinical documents.
Apyx Medical (NASDAQ:APYX) reported Q3 2025 total revenue $12.9M, up from $11.5M a year earlier, driven by Surgical Aesthetics $11.1M (+19%) and domestic sales rising over 30%.
Gross margin improved to 64.4%. Net loss attributable to stockholders narrowed to $2.0M (Q3 2024: $4.7M). Adjusted EBITDA loss fell to $0.1M from $2.4M.
The company launched commercial U.S. sales of the AYON Body Contouring System in September 2025, received 510(k) clearance in May 2025, and filed an additional 510(k) in October 2025 to add power liposuction labeling. Full-year 2025 revenue guidance was raised to $50.5M–$52.5M.